Latest Breaking News On - Agenus inc - Page 11 : comparemela.com

Agenus: A Would-Be Rockstar Held Back By Middling Financials (NASDAQ:AGEN)

Agenus: A Would-Be Rockstar Held Back By Middling Financials (NASDAQ:AGEN)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Botensilimab balstilimabStevena cohenBristol myers squibbDefense threat reduction agencyDepartment of defenseAgenus incCorporate presentationGinkgo bioworks

Vaccine Adjuvants Market Global Industry Analysis

Dublin, Feb. 21, 2024 (GLOBE NEWSWIRE) The

United statesCroda international plcAgenus incGsk plcPhibro animal health corporationMerck kgaaVaxine pty ltdAdjuvants marketIndustry sizeGlobal vaccine adjuvants marketAmerica dominatesVaccine adjuvants landscapeRegulatory excellence encourages marketNorth americanVaccine adjuvantsCommercial applications lead market

Agenus Inc (NASDAQ:AGEN) Insider Garo H Armen Purchases 500,000 Shares of Stock

Agenus Inc. (NASDAQ:AGEN – Get Free Report) insider Garo H. Armen bought 500,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was purchased at an average price of $0.65 per share, for a total transaction of $325,000.00. Following the transaction, the insider now owns 625,969 shares of the company’s […]

United statesGaroh armenSigma securitiesSg americas securitiesS capital wealth advisorsAgenus company profileCommonwealth equity servicesAgenus incSei investments coGet free reportWealth advisorsEquity servicesTwo sigma securitiesRetrocyte displayAgenus dailyNasdaq agen

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

BOSTON and LEXINGTON, Mass., Feb. 15, 2024 /PRNewswire/ The Defense Threat Reduction Agency s Joint Science and Technology Office for the Chemical and Biological Defense Program has awarded,.

United statesRebecca kurnatJennifer wipfAdjuvant developmentSaponiqx incDefense consortiumDefense threat reduction agencyExchange commissionGinkgo bioworks incTechnology officeAgenus incJoint scienceBiological defenseVaccines prototypeGinkgo bioworksGenerative molecular design

GSK s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk -February 06, 2024 at 07:04 am EST

Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population Adults aged 50 and above with underlying medical.

United kingdomUnited kingdom generalJ clin virolRichard osei yeboahSaponiqx incCenters for diseaseAgenus incAntigenics incDrug administrationPriority reviewRespiratory syncytial virus vaccinePriority review voucherBiologics license applicationPrescription drug user fee actSyncytial virus vaccineSafety information